The Bank of New York
101 Barclay Street, 22W
New York, NY 10286
USA










March 7, 2006

SECURITIES & EXCHANGE COMMISSION
450 Fifth Street, NW
Washington, DC 20549

Attn.: Document Control



RE:	American Depositary Shares evidenced
by the American Depositary Receipts
each representing Ten Ordinary Shares
of Epitan Limited
 (Form F-6 File No. 333-116721)



Ladies and Gentlemen:

Pursuant to Rule 424(b)(3) under the Securities
Act of 1933, as amended, on behalf of The Bank
of New York, as Depositary for securities
against which American Depositary Receipts are
to be issued, we attach a copy of the new
prospectus (Prospectus) reflecting the change in
name to Clinuvel Pharmaceuticals Limited of ten
(10) ordinary shares represented by one
American Depositary Share (the Ratio).

As required by Rule 424(e), the upper right hand
corner of the Prospectus cover page has a
reference to Rule 424(b)(3) and to the file
number of the registration statement to which the
Prospectus relates.

Pursuant to Section III B of the General
Instructions to the Form F-6 Registration
Statement, the Prospectus consists of the ADR
certificate with revised name change for Epitan
Limited.

The Prospectus has been revised to reflect
the new name from Epitan Limited to Clinuvel
Pharmaceuticals Limited.

 EFFECTIVE March 3, 2006, THE
COMPANYS NAME HAS CHANGED FROM
EPITAN LIMITED TO CLINUVEL
PHARMACEUTICALS LIMITED.

Please contact me with any questions or
comments at 212 815-2276.


Violet Pagan
Assistant Vice President
The Bank of New York - ADR Division


Encl.CC: Paul Dudek, Esq. (Office of
International Corporate Finance)